Compare DLTH & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTH | INO |
|---|---|---|
| Founded | 1989 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 133.4M |
| IPO Year | 2015 | 1999 |
| Metric | DLTH | INO |
|---|---|---|
| Price | $3.63 | $1.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $7.00 | $6.75 |
| AVG Volume (30 Days) | 40.4K | ★ 4.7M |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.12 | 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $565,184,000.00 | $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | $2.80 | $421.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $2.02 | $0.56 |
| 52 Week High | $5.09 | $2.86 |
| Indicator | DLTH | INO |
|---|---|---|
| Relative Strength Index (RSI) | 32.93 | 64.40 |
| Support Level | $3.65 | $1.03 |
| Resistance Level | $4.68 | $1.79 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 15.63 | 86.36 |
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.